PFIZER INC.

DelveInsight's 'Adrenoleukodystrophy Pipeline Insight, 2024' report details 11+ treatment therapies by 10+ companies, including Autobahn Therapeutics, Viking Therapeutics, and SwanBio Therapeutics. Emerging therapies like ABX-002, VK0214, and SBT101 are expected to impact the market. Minoryx Therapeutics plans to re-examine Nezglyal's approval after CHMP's refusal.

Researchers found ponsegromab, a drug blocking GDF-15 hormone, effectively treats cachexia in cancer patients, improving symptoms with minimal side effects, according to a phase 2 clinical trial published in the New England Journal of Medicine.

Lauren Flynn Kelly, a health business journalist since the early 2000s, specializes in Medicare Advantage, managed Medicaid, and Medicare Part D. She has extensive experience in pharmacy benefit management and currently manages Radar on Medicare Advantage and AIS Health’s publications.

The Liberal National Coalition believes in Australia's life sciences and biotech sector's potential, highlighting strengths like health research, clinical trials, and biotech companies. The speaker criticizes current Labor Government policies for hindering sector growth, citing funding cuts and anti-business policies. They advocate for a Coalition approach focusing on commercializing research, attracting private investment, leveraging sector strengths, and avoiding picking winners, as demonstrated in past policies like the Medical Research Future Fund and National Innovation and Science Agenda.

Researchers found a drug, ponsegromab, effectively treats cachexia in cancer patients by blocking the GDF-15 hormone, improving symptoms with minimal side effects, as reported in a phase 2 clinical trial in the New England Journal of Medicine.

Roche's Xofluza reduced flu transmission in households in a Phase 3 study, marking the first time an antiviral has shown such efficacy in a global trial. The study involved over 4,000 participants aged 5-64, with no new safety concerns identified. Full data will be presented at an upcoming medical meeting.

The 'Crohn's Disease - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides insights on 70+ companies and 80+ pipeline drugs, including clinical and nonclinical stage products, therapeutic assessments, and emerging drugs like Ozanimod, Etrasimod, CBP-307, and IMU-856. The report highlights the current scenario and growth prospects in Crohn's Disease treatment, focusing on novel approaches and key players in the field.

Pharmaceutical industry inefficiencies stem from high costs per drug approval, frequent C-level executive changes, and strategic R&D restructuring unrelated to science. AI-drug discovery companies should commit to programs until Phase I completion to avoid waste and maximize patient benefit.

Organon plans to acquire Dermavant for up to $1.2 billion, gaining its commercialized plaque psoriasis drug Vtama, which is under FDA review for atopic dermatitis. Vtama sales grew to $75.1 million in FY2023, but face competition in a crowded market. Organon aims to leverage its global scale to expand Vtama's reach.

Novartis' Kisqali gains broad FDA approval for early HR+/HER2- breast cancer, reducing recurrence risk by 25% in NATALEE trial, surpassing Eli Lilly's Verzenio in node-negative cases. Kisqali's potential to reach $7 billion in sales is boosted by this approval.